Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "inhaler"

38 News Found

North America accounts for 50 % of generic pharma market
News | December 03, 2021

North America accounts for 50 % of generic pharma market

Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively


Lupin partners with TTP for soft-mist inhalation tech platform
Biotech | December 02, 2021

Lupin partners with TTP for soft-mist inhalation tech platform

Soft-mist inhalation (SMI) technology allows for delivery of inhalation drugs from a small, portable hand-held inhaler device without the use of propellants


Amrutanjan Health Care opens first store in Chennai
News | December 02, 2021

Amrutanjan Health Care opens first store in Chennai

The offline store launch will complement the E-commerce website in building a rich consumer shopping experience


Glenmark launches Tavulus for COPD treatment in Spain
Drug Approval | October 11, 2021

Glenmark launches Tavulus for COPD treatment in Spain

It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK


Lupin launches Luforbec to treat asthma & COPD in UK
News | August 24, 2021

Lupin launches Luforbec to treat asthma & COPD in UK

It is the first branded generic alternative to Fostair 100/6 pMDI


Lupin launches Digital Asthma Educator platform
News | June 08, 2021

Lupin launches Digital Asthma Educator platform

The new platform is the latest initiative under Lupin’s long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailment


Glenmark’s Ryaltris nasal spray approved in Europe
News | April 27, 2021

Glenmark’s Ryaltris nasal spray approved in Europe

In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark


Cadila Healthcare Q3FY21 consolidated PAT up at Rs. 527.2 Cr
News | February 06, 2021

Cadila Healthcare Q3FY21 consolidated PAT up at Rs. 527.2 Cr

The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.